Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 20.2 kDa. The protein migrates as 21-23 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human BAFF Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Biotinylated Human BAFF Protein, His,Avitag (Cat. No. BAF-H82Q2) is more than 90% and the molecular weight of this protein is around 60-75 kDa verified by SEC-MALS.
Immobilized Human BCMA, Fc Tag (Cat. No. BC7-H5254) at 2 μg/mL (100 μL/well) can bind Biotinylated Human BAFF Protein, His,Avitag (Cat. No. BAF-H82Q2) with a linear range of 0.2-4 ng/mL (QC tested).
Immobilized Human TACI Protein, Fc Tag at 2 μg/mL (100 μL/well) can bind Biotinylated Human BAFF Protein, His,Avitag (Cat. No. BAF-H82Q2) with a linear range of 0.2-3 ng/mL (Routinely tested).
Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) and 0.01 μg/mL (100 μL/well) Biotinylated Human BAFF, His,Avitag (Cat. No. BAF-H82Q2) with a half maximal inhibitory concentration (IC50) of 14.79 μg/mL (Routinely tested).
Serial dilutions of Anti-BAFFR Antibody, Human IgG1 were added into Human BAFFR Protein, Llama IgG2b Fc Tag (Cat. No. BAR-H5258): Biotinylated Human BAFF Protein, His,Avitag (Cat. No. BAF-H82Q2) binding reactions. The half maximal inhibitory concentration (IC50) is 1.1323 μg/mL (Routinely tested).
Serial dilutions of Anti-BAFFR Antibody, Human IgG1 were added into Human BAFFR, Fc Tag (Cat. No. BAR-H5257): Biotinylated Human BAFF Protein, His,Avitag (Cat. No. BAF-H82Q2) binding reactions. The half maximal inhibitory concentration (IC50) is 0.7363 μg/mL (Routinely tested).
Immobilized Biotinylated Human BAFF Protein, His,Avitag (Cat. No. BAF-H82Q2) on SA Chip can bind Human TACI Protein, Fc Tag with an affinity constant of 1.35 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Immobilized Biotinylated Human BAFF Protein, His,Avitag (Cat. No. BAF-H82Q2) on SA Chip can bind Human BAFFR Protein, Llama IgG2b Fc Tag (Cat. No. BAR-H5258) with an affinity constant of 35.3 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Biotinylated Human BAFF Protein, His,Avitag (Cat. No. BAF-H82Q2) on SA Biosensor, can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 1.1 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Price(USD) : $350.00
Price(USD) : $1520.00
Price(USD) : $32.00
Price(USD) : $137.00
Price(USD) : $50.00
Price(USD) : $120.00
Price(USD) : $138.00
Price(USD) : $230.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Telitacicept | RCT-18; RC-18; RCT18; RC18 | Approved | RemeGen Co Ltd | 泰爱 | Mainland China | Lupus Erythematosus, Systemic | RemeGen Co Ltd | 2021-03-09 | Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Lupus Erythematosus, Systemic; Neuromyelitis Optica | Details |
Belimumab | BmAb; HGS-1006; GSK-1550188 | Approved | Glaxosmithkline Plc | Benlysta, 倍力腾 | Mainland China | Lupus Nephritis | Glaxosmithkline (China) Investment Co Ltd | 2011-03-09 | Glomerulonephritis, Membranous; Leukemia, Lymphocytic, Chronic, B-Cell; Pulmonary Disease, Chronic Obstructive; Waldenstrom Macroglobulinemia; Emphysema; Lymphopenia; Sjogren-Larsson Syndrome; Lupus Erythematosus, Systemic; Antiphospholipid Syndrome; Rejection of renal transplantation; Lupus Nephritis; Purpura; Graft vs Host Disease; Arthritis, Rheumatoid; Myositis; Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
hCBE-11 | hCBE-11 | Biogen Inc | Details | ||
UBP-1213 | UBP-1213 | Phase 1 Clinical | Wuhan Huaxin Kangyuan Biomedicine Co Ltd, Shanghai Junshi Biosciences Co Ltd | Lupus Erythematosus, Systemic | Details |
Tabalumab | LY-2127399 | Phase 2 Clinical | Eli Lilly And Company | Multiple Sclerosis, Relapsing-Remitting; Dermatomyositis; Arthritis, Rheumatoid; Autoimmune Diseases; Scleroderma, Systemic; Multiple Myeloma; Connective Tissue Diseases; Arthritis, Juvenile; Multiple Sclerosis; Lupus Erythematosus, Systemic; Kidney Failure, Chronic; Pemphigus | Details |
Atacicept | TACI-Ig | Phase 3 Clinical | Zymogenetics Inc | Glomerulonephritis, IGA; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Lupus Erythematosus, Systemic | Details |
Rozibafusp alfa | AMG-570; MEDI-0700 | Phase 2 Clinical | Amgen Inc | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic | Details |
This web search service is supported by Google Inc.